KYMR
Kymera Therapeutics, Inc.
Price Chart
Latest Quote
$116.46
+16.59 (+16.61%)
Current Price
| Previous Close | $99.87 |
| Open | $108.88 |
| Day High | $130.05 |
| Day Low | $106.17 |
| Volume | 3,856,806 |
Stock Information
| Shares Outstanding | 82.26M |
| Total Debt | $80.47M |
| Cash Equivalents | $650.93M |
| Revenue | $51.48M |
| Net Income | $-315.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.58B |
| EPS (TTM) | $-3.58 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.64B |
| Sales | $51.48M |
| Income | $-315.00M |
| Book/sh | $18.73 |
| Cash/sh | $7.91 |
| Employees | 253 |
Financial Ratios
| Quick Ratio | 10.39 |
| Current Ratio | 10.81 |
| Debt/Eq | 5.23 |
Returns & Margins
| ROA | -17.16% |
| ROE | -27.09% |
| Operating Margin | -244.88% |
Ownership
| Insider Ownership | 2.10% |
| Institutional Ownership | 117.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -26.80 |
| P/S | 186.10 |
| P/B | 6.22 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $119.19 |
Technical Indicators
| SMA20 | $85.01 |
| SMA50 | $84.33 |
| SMA200 | $74.76 |
| RSI | 94.71 |
| ATR | 6.7315 |
| Shares Float | 55.03M |
| Short Float | 15.85% |
| Short Ratio | 19.79 |
| Volatility | 2.03 |
| Rel Volume | 3.78 |
Performance History
| Week | +29.54% |
| Month | +44.19% |
| Quarter | +47.55% |
| 6 Months | +38.07% |
| YTD | +60.06% |
| Year | +147.05% |
| 3 Years | +362.33% |
| 5 Years | +144.36% |
| 10 Years | +250.15% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $116.46 | 3,856,806 |
| 2026-06-24 | $99.87 | 1,302,300 |
| 2026-06-23 | $98.25 | 1,368,200 |
| 2026-06-22 | $99.45 | 2,891,000 |
| 2026-06-18 | $90.43 | 1,262,300 |
| 2026-06-17 | $89.90 | 1,092,500 |
| 2026-06-16 | $87.44 | 588,100 |
| 2026-06-15 | $85.59 | 485,100 |
| 2026-06-12 | $86.21 | 625,200 |
| 2026-06-11 | $82.96 | 674,500 |
| 2026-06-10 | $78.23 | 604,800 |
| 2026-06-09 | $76.91 | 748,300 |
| 2026-06-08 | $73.95 | 453,700 |
| 2026-06-05 | $74.13 | 639,400 |
| 2026-06-04 | $74.61 | 752,700 |
| 2026-06-03 | $73.21 | 860,600 |
| 2026-06-02 | $71.29 | 837,000 |
| 2026-06-01 | $78.47 | 437,500 |
| 2026-05-29 | $81.42 | 587,300 |
| 2026-05-28 | $81.46 | 316,800 |
| 2026-05-27 | $81.70 | 330,300 |
| 2026-05-26 | $80.77 | 503,100 |
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
đ° Latest News
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
Investor's Business Daily âĸ 2026-06-25T20:57:27Z
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires âĸ 2026-06-25T19:48:41ZKymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-23T14:24:00Z
Brookline Capital Markets Increases Price Target for Kymera Therapeutics (KYMR)
Insider Monkey âĸ 2026-06-11T10:20:40Z
Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound
Simply Wall St. âĸ 2026-06-11T02:11:47Z
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Zacks âĸ 2026-06-10T14:48:00Z
How The Kymera Therapeutics (KYMR) Investment Narrative Is Evolving Without New Analyst Targets
Simply Wall St. âĸ 2026-06-03T18:11:43Z
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
Insider Monkey âĸ 2026-06-02T13:55:49Z
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
MarketBeat âĸ 2026-05-26T13:06:26Z
Boxer Capitalâs $18 Million Corvus Pharma Bet Signals Confidence in This Biotechâs Next Phase
Motley Fool âĸ 2026-05-17T20:46:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $39,211,000 | $47,072,000 | $78,592,000 | $46,826,000 |
| Operating Revenue | $39,211,000 | $47,072,000 | $78,592,000 | $46,826,000 |
| Expenses | ||||
| Interest Expense | $370,000 | $249,000 | $196,000 | $176,000 |
| Total Expenses | $384,755,000 | $303,782,000 | $244,122,000 | $208,082,000 |
| Other Income Expense | $-3,855,000 | $-4,925,000 | - | - |
| Net Non Operating Interest Income Expense | $38,048,000 | $37,777,000 | $18,568,000 | $6,448,000 |
| Interest Expense Non Operating | $370,000 | $249,000 | $196,000 | $176,000 |
| Operating Expense | $384,755,000 | $303,782,000 | $244,122,000 | $208,082,000 |
| General And Administrative Expense | $68,187,000 | $63,534,000 | $55,041,000 | $43,834,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Net Interest Income | $38,048,000 | $37,777,000 | $18,568,000 | $6,448,000 |
| Interest Income | $38,418,000 | $38,026,000 | $18,764,000 | $6,624,000 |
| Normalized Income | $-307,496,000 | $-218,933,000 | $-146,962,000 | $-154,808,000 |
| Net Income From Continuing And Discontinued Operation | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Total Operating Income As Reported | $-349,399,000 | $-261,635,000 | $-165,530,000 | $-161,256,000 |
| Net Income Common Stockholders | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Net Income | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Net Income Including Noncontrolling Interests | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Net Income Continuous Operations | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Pretax Income | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Special Income Charges | $-3,855,000 | $-4,925,000 | $0 | $0 |
| Interest Income Non Operating | $38,418,000 | $38,026,000 | $18,764,000 | $6,624,000 |
| Operating Income | $-345,544,000 | $-256,710,000 | $-165,530,000 | $-161,256,000 |
| Per Share | ||||
| Diluted EPS | $-3.69 | $-2.98 | $-2.52 | $-2.87 |
| Basic EPS | $-3.69 | $-2.98 | $-2.52 | $-2.87 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-298,813,000 | $-211,311,000 | $-143,201,000 | $-151,655,000 |
| Total Unusual Items | $-3,855,000 | $-4,925,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-3,855,000 | $-4,925,000 | $0 | $0 |
| Reconciled Depreciation | $8,313,000 | $7,373,000 | $3,565,000 | $2,977,000 |
| EBITDA (Bullshit earnings) | $-302,668,000 | $-216,236,000 | $-143,201,000 | $-151,655,000 |
| EBIT | $-310,981,000 | $-223,609,000 | $-146,766,000 | $-154,632,000 |
| Diluted Average Shares | $84,490,585 | $75,043,991 | $58,365,499 | $53,933,229 |
| Basic Average Shares | $84,490,585 | $75,043,991 | $58,365,499 | $53,933,229 |
| Diluted NI Availto Com Stockholders | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Impairment Of Capital Assets | $3,855,000 | $4,925,000 | $0 | $0 |
| Research And Development | $316,568,000 | $240,248,000 | $189,081,000 | $164,248,000 |
| Selling General And Administration | $68,187,000 | $63,534,000 | $55,041,000 | $43,834,000 |
| Other Gand A | $68,187,000 | $63,534,000 | $55,041,000 | $43,834,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Total Assets | $1,742,812,000 | $978,035,000 | $575,759,000 | $603,134,000 |
| Total Non Current Assets | $871,598,000 | $467,767,000 | $170,442,000 | $183,718,000 |
| Other Non Current Assets | $14,914,000 | $7,744,000 | $7,929,000 | $9,147,000 |
| Investmentin Financial Assets | $771,158,000 | $362,159,000 | $61,434,000 | $152,328,000 |
| Current Assets | $871,214,000 | $510,268,000 | $405,317,000 | $419,416,000 |
| Other Current Assets | $22,938,000 | $21,524,000 | $11,674,000 | $9,713,000 |
| Cash Cash Equivalents And Short Term Investments | $848,276,000 | $488,744,000 | $374,881,000 | $407,166,000 |
| Cash And Cash Equivalents | $357,011,000 | $120,256,000 | $109,966,000 | $68,395,000 |
| Receivables | - | $947,000 | $18,762,000 | $2,537,000 |
| Other Receivables | - | $947,000 | $3,762,000 | $2,537,000 |
| Accounts Receivable | - | $0 | $15,000,000 | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $82,252,000 | $87,761,000 | $84,674,000 | $17,335,000 |
| Long Term Debt And Capital Lease Obligation | $68,496,000 | $74,649,000 | $78,329,000 | $13,392,000 |
| Current Debt And Capital Lease Obligation | $13,756,000 | $13,112,000 | $6,345,000 | $3,943,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $163,148,000 | $142,416,000 | $180,788,000 | $112,983,000 |
| Total Non Current Liabilities Net Minority Interest | $79,936,000 | $74,649,000 | $95,097,000 | $41,640,000 |
| Non Current Deferred Liabilities | $11,440,000 | $0 | $16,768,000 | $28,000,000 |
| Current Liabilities | $83,212,000 | $67,767,000 | $85,691,000 | $71,343,000 |
| Other Current Liabilities | $242,000 | $223,000 | $524,000 | $303,000 |
| Current Deferred Liabilities | $22,925,000 | $13,576,000 | $37,883,000 | $35,260,000 |
| Payables And Accrued Expenses | $46,289,000 | $40,856,000 | $40,939,000 | $31,837,000 |
| Payables | $4,015,000 | $5,989,000 | $7,075,000 | $4,335,000 |
| Accounts Payable | $4,015,000 | $5,989,000 | $7,075,000 | $4,335,000 |
| Other Non Current Liabilities | - | - | - | $248,000 |
| Equity | ||||
| Common Stock Equity | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Total Equity Gross Minority Interest | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Stockholders Equity | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Gains Losses Not Affecting Retained Earnings | $1,800,000 | $-1,485,000 | $-552,000 | $-4,949,000 |
| Other Equity Adjustments | $1,800,000 | $-1,485,000 | $-552,000 | $-4,949,000 |
| Retained Earnings | $-1,065,961,000 | $-754,610,000 | $-530,752,000 | $-383,790,000 |
| Other | ||||
| Ordinary Shares Number | $81,323,532 | $64,890,193 | $55,585,305 | $55,039,380 |
| Share Issued | $81,323,532 | $64,890,193 | $55,585,305 | $55,039,380 |
| Tangible Book Value | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Invested Capital | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Working Capital | $788,002,000 | $442,501,000 | $319,626,000 | $348,073,000 |
| Capital Lease Obligations | $82,252,000 | $87,761,000 | $84,674,000 | $17,335,000 |
| Total Capitalization | $1,579,664,000 | $835,619,000 | $394,971,000 | $490,151,000 |
| Additional Paid In Capital | $2,643,817,000 | $1,591,707,000 | $926,269,000 | $878,884,000 |
| Capital Stock | $8,000 | $7,000 | $6,000 | $6,000 |
| Common Stock | $8,000 | $7,000 | $6,000 | $6,000 |
| Preferred Stock | $0 | $0 | - | - |
| Non Current Deferred Revenue | $11,440,000 | $0 | $16,768,000 | $28,000,000 |
| Long Term Capital Lease Obligation | $68,496,000 | $74,649,000 | $78,329,000 | $13,392,000 |
| Current Deferred Revenue | $22,925,000 | $13,576,000 | $37,883,000 | $35,260,000 |
| Current Capital Lease Obligation | $13,756,000 | $13,112,000 | $6,345,000 | $3,943,000 |
| Current Accrued Expenses | $42,274,000 | $34,867,000 | $33,864,000 | $27,502,000 |
| Investments And Advances | $771,158,000 | $362,159,000 | $61,434,000 | $152,328,000 |
| Available For Sale Securities | $771,158,000 | $362,159,000 | $61,434,000 | $152,328,000 |
| Net PPE | $85,526,000 | $97,864,000 | $101,079,000 | $22,243,000 |
| Accumulated Depreciation | $-22,127,000 | $-16,073,000 | $-10,440,000 | $-6,893,000 |
| Gross PPE | $107,653,000 | $113,937,000 | $111,519,000 | $29,136,000 |
| Leases | $42,991,000 | $44,010,000 | $7,802,000 | $7,802,000 |
| Other Properties | $53,739,000 | $57,933,000 | $42,401,000 | $5,529,000 |
| Machinery Furniture Equipment | $10,923,000 | $11,994,000 | $8,371,000 | $6,896,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $491,265,000 | $368,488,000 | $264,915,000 | $338,771,000 |
| Buildings And Improvements | - | $47,407,000 | $52,945,000 | $8,909,000 |
| Construction In Progress | - | - | - | $1,146,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-234,340,000 | $-207,339,000 | $-137,306,000 | $-155,921,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-232,891,000 | $-194,501,000 | $-102,826,000 | $-153,085,000 |
| Cash Flow From Continuing Operating Activities | $-232,891,000 | $-194,501,000 | $-102,826,000 | $-153,085,000 |
| Operating Gains Losses | - | - | $-5,229,000 | $889,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,449,000 | $-12,838,000 | $-34,480,000 | $-2,836,000 |
| Investing Cash Flow | $-521,061,000 | $-404,077,000 | $139,886,000 | $20,519,000 |
| Cash Flow From Continuing Investing Activities | $-521,061,000 | $-404,077,000 | $139,886,000 | $20,519,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $928,901,000 | $596,619,000 | $0 | $149,825,000 |
| Financing Cash Flow | $990,713,000 | $608,851,000 | $4,192,000 | $152,999,000 |
| Cash Flow From Continuing Financing Activities | $990,713,000 | $608,851,000 | $4,192,000 | $152,999,000 |
| Net Common Stock Issuance | $928,901,000 | $596,619,000 | $0 | $149,825,000 |
| Common Stock Issuance | $928,901,000 | $596,619,000 | $0 | $149,825,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-1,494,000 | $-1,576,000 | $-76,000 | $-1,130,000 |
| Interest Paid Supplemental Data | $312,000 | $206,000 | $162,000 | $179,000 |
| End Cash Position | $362,811,000 | $126,050,000 | $115,777,000 | $74,525,000 |
| Beginning Cash Position | $126,050,000 | $115,777,000 | $74,525,000 | $54,092,000 |
| Changes In Cash | $236,761,000 | $10,273,000 | $41,252,000 | $20,433,000 |
| Proceeds From Stock Option Exercised | $63,306,000 | $13,808,000 | $4,268,000 | $4,304,000 |
| Net Issuance Payments Of Debt | $-1,494,000 | $-1,576,000 | $-76,000 | $-1,130,000 |
| Net Long Term Debt Issuance | $-1,494,000 | $-1,576,000 | $-76,000 | $-1,130,000 |
| Long Term Debt Payments | $-1,494,000 | $-1,576,000 | $-76,000 | $-1,130,000 |
| Net Investment Purchase And Sale | $-519,612,000 | $-391,239,000 | $174,366,000 | $23,355,000 |
| Sale Of Investment | $488,016,000 | $509,987,000 | $363,517,000 | $469,327,000 |
| Purchase Of Investment | $-1,007,628,000 | $-901,226,000 | $-189,151,000 | $-445,972,000 |
| Net PPE Purchase And Sale | $-1,449,000 | $-12,838,000 | $-34,480,000 | $-2,836,000 |
| Purchase Of PPE | $-1,449,000 | $-12,838,000 | $-34,480,000 | $-2,836,000 |
| Change In Working Capital | $15,266,000 | $-23,970,000 | $2,682,000 | $-37,623,000 |
| Change In Other Working Capital | $13,643,000 | $-41,217,000 | $-7,728,000 | $-38,515,000 |
| Change In Other Current Liabilities | $-5,042,000 | $1,921,000 | $18,582,000 | $-1,004,000 |
| Change In Other Current Assets | $2,666,000 | $2,541,000 | $4,797,000 | $517,000 |
| Change In Payables And Accrued Expense | $5,413,000 | $3,873,000 | $5,218,000 | $4,772,000 |
| Change In Accrued Expense | $7,387,000 | $4,180,000 | $3,180,000 | $4,519,000 |
| Change In Payable | $-1,974,000 | $-307,000 | $2,038,000 | $253,000 |
| Change In Account Payable | $-1,974,000 | $-307,000 | $2,038,000 | $253,000 |
| Change In Prepaid Assets | $-2,361,000 | $-8,903,000 | $-1,961,000 | $-992,000 |
| Change In Receivables | $947,000 | $17,815,000 | $-16,226,000 | $-2,401,000 |
| Changes In Account Receivables | $0 | $15,000,000 | $-15,000,000 | $0 |
| Stock Based Compensation | $59,904,000 | $55,012,000 | $43,118,000 | $35,480,000 |
| Asset Impairment Charge | $3,856,000 | $4,925,000 | $0 | $0 |
| Amortization Of Securities | $-8,879,000 | $-13,983,000 | $-5,229,000 | $889,000 |
| Depreciation Amortization Depletion | $8,313,000 | $7,373,000 | $3,565,000 | $2,977,000 |
| Depreciation And Amortization | $8,313,000 | $7,373,000 | $3,565,000 | $2,977,000 |
| Net Income From Continuing Operations | $-311,351,000 | $-223,858,000 | $-146,962,000 | $-154,808,000 |
| Gain Loss On Investment Securities | - | - | $-5,229,000 | $889,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
Fetched: 2026-06-24